Patents by Inventor James F. Young
James F. Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7700735Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: GrantFiled: March 1, 2001Date of Patent: April 20, 2010Assignee: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herron Wu, Jeffrey D. Watkins
-
Publication number: 20100028948Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: June 1, 2009Publication date: February 4, 2010Applicant: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7635568Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: July 26, 2004Date of Patent: December 22, 2009Assignee: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7553489Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: December 20, 2006Date of Patent: June 30, 2009Assignee: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20090130111Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: ApplicationFiled: September 28, 2006Publication date: May 21, 2009Applicant: MEDIMMUNE, INC.Inventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Patent number: 7323172Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: October 8, 2004Date of Patent: January 29, 2008Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7229619Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2000Date of Patent: June 12, 2007Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7179900Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: March 31, 2003Date of Patent: February 20, 2007Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 6855493Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2001Date of Patent: February 15, 2005Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins
-
Patent number: 6818216Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2001Date of Patent: November 16, 2004Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson
-
Publication number: 20040131609Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: September 8, 2003Publication date: July 8, 2004Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20040096451Abstract: The present invention relates to methods for broad spectrum prevention and treatment of viral respiratory infection. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with respiratory syncytial virus (RSV), parainfluenza virus (PIV), and/or human metapneumovirus (hMPV) infection, the methods comprising administering to a subject an effective amount of one or more anti-RSV-antigen antibodies or antigen-binding fragments thereof, one or more anti-hMPV-antigen antibodies or antigen-binding fragments thereof, and/or one or more anti-PIV-antigen antibodies or antigen-binding fragments thereof. In certain embodiments, a certain serum titer of the anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof is achieved in said subject.Type: ApplicationFiled: July 25, 2003Publication date: May 20, 2004Inventors: James F. Young, Peter Kiener, Albertus Dominicus Marcellinus Erasmus Osterhaus, Ronaldus Adrianus Maria Fouchier
-
Patent number: 6656467Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: GrantFiled: January 26, 2001Date of Patent: December 2, 2003Assignees: MedImmune, Inc., Applied Molecular EvolutionInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20030091584Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: November 28, 2001Publication date: May 15, 2003Inventors: James F. Young, Scott Koenig, Leslie S. Johnson
-
Publication number: 20020177126Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: November 28, 2001Publication date: November 28, 2002Applicant: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson
-
Publication number: 20020164326Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: January 26, 2001Publication date: November 7, 2002Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20020098189Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: ApplicationFiled: March 1, 2001Publication date: July 25, 2002Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 5760941Abstract: An optical encoding and decoding system which performs code-division multiple access (CDMA) communication in the incoherent, or direct detection, optical domain using bipolar +1/-1 codes. The present invention uses code modulation and detection principles that permit all-optical implementation of the bipolar, +1/-1, code and correlation detection that have been developed for the radio frequency (RF) systems. This is possible in spite of the non-negative, or unipolar, +1/0, nature of the incoherent optical system that only detects and processes the signal intensity. The unipolar optical system of the present invention is equivalent to the bipolar RF system in that the correlation properties of the bipolar codes is completely preserved. The optical CDMA system can be realized both in time or frequency domain encoding with all-optical components.Type: GrantFiled: February 29, 1996Date of Patent: June 2, 1998Assignee: Rice UniversityInventors: James F. Young, Benhaam Aazhang, Lim Nguyen
-
Patent number: 5549753Abstract: Molded fibrous workpieces of various cross sectional configurations are coated with a polymeric latex foam coating material to encapsulate fibers and dust within the exterior surfaces of the workpieces. The foam coating is applied by passing the workpieces through a coating chamber filled with the polymeric foam so that the workpieces are totally immersed in the foam coating as the workpieces pass through the chamber. Openings for introducing the workpieces into and discharging the workpieces from the chamber have a configuration complementary to the transverse configuration of the workpieces. The foam coating is introduced into the chamber both above and below the path of the workpieces through the coating chamber to assure that the coating chamber remains fully charged with the foam coating. Brushes or wiper blades spread the foam coating over the exterior surfaces of the workpieces.Type: GrantFiled: April 12, 1995Date of Patent: August 27, 1996Assignee: Schuller International, Inc.Inventors: Kent R. Matthews, Eric G. Schakel, Lowell K. Morton, James F. Young
-
Patent number: 5514417Abstract: Molded fibrous workpieces of various cross sectional configurations are coated with a polymeric latex foam coating material to encapsulate fibers and dust within the exterior surfaces of the workpieces. The foam coating is applied by passing the workpieces through a coating chamber filled with the polymeric foam so that the workpieces are totally immersed in the foam coating as the workpieces pass through the chamber. Openings for introducing the workpieces into and discharging the workpieces from the chamber have a configuration complementary to the transverse configuration of the workpieces. The foam coating is introduced into the chamber both above and below the path of the workpieces through the coating chamber to assure that the coating chamber remains fully charged with the foam coating. Brushes or wiper blades spread the foam coating over the exterior surfaces of the workpieces.Type: GrantFiled: August 4, 1994Date of Patent: May 7, 1996Assignee: Schuller International, Inc.Inventors: Kent R. Matthews, Eric G. Schakel, Lowell K. Morton, James F. Young